Physician profile
Damaris Vega
NPI 1447351176
$564,771.22
in general payments reported to CMS, 2019-2025
89 companies · $78K in 2025
The $78K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $133K · 2020: $46K · 2021: $33K · 2022: $125K · 2023: $94K · 2024: $56K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188K · Food and Beverage: $16K · Travel and Lodging: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,213 · Consulting Fee: $3,700 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $187,604.19 |
| Food and Beverage | $16,498.80 |
| Travel and Lodging | $15,557.63 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,213.00 |
| Consulting Fee | $3,700.00 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $340,255.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $154,002.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,130.94 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $12,310.99 | 2019-2022 | |
| Intuity Medical INC | $6,159.63 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Dexcom, INC. | $5,442.85 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Eli Lilly and Company | $3,657.84 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $2,579.20 | 2019-2020 | |
| Sandoz INC. | $2,462.81 | 2024-2025 | |
| Insulet Corporation | $2,366.97 | 2019-2025 | Omnipod |
| Medtronic Minimed, INC. | $1,501.55 | 2019-2020 | |
| Amgen INC. | $1,336.57 | 2019-2025 | Tepezza, Repatha, Evenity |
| Sanofi-Aventis U.S. LLC | $1,258.62 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $1,216.20 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $780.88 | 2019-2025 | Korlym |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $669.06 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $668.63 | 2021-2025 | |
| Valeritas, INC. | $609.92 | 2019 | |
| Amneal Pharmaceuticals LLC | $603.53 | 2019-2025 | Unithroid |
| Abbvie INC. | $559.35 | 2019-2025 | Synthroid |
| Xeris Pharmaceuticals, INC. | $559.26 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $502.14 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $440.12 | 2019-2024 | Afrezza, V-Go |
| Beta Bionics, INC. | $418.02 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $362.65 | 2022-2025 | Cequr Simplicity |
| Radius Health, INC. | $345.15 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $343.31 | 2019-2021 | |
| Esperion Therapeutics, INC. | $327.83 | 2020-2025 | Nexletol |
| Becton, Dickinson and Company | $295.41 | 2019-2022 | |
| Antares Pharma, INC. | $277.36 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $262.92 | 2024-2025 | Veozah |
| Medtronic, INC. | $253.24 | 2021-2024 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $249.74 | 2019-2025 | Strensiq |
| Ibsa Pharma INC. | $248.84 | 2019-2024 | Tirosint, Licart, Licart |
| Grt US Holding, INC. | $199.87 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $186.40 | 2022-2025 | |
| Sequel Med Tech, LLC | $185.21 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $181.66 | 2025 | |
| Horizon Therapeutics Plc | $170.00 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $168.99 | 2023-2025 | Isturisa, Signifor Lar |
| Embecta Corp. | $167.95 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Madrigal Pharmaceuticals | $164.58 | 2025 | Rezdiffra |
| Pfizer INC. | $151.88 | 2019-2024 | |
| Ge Healthcare | $141.94 | 2025 | |
| Clarus Therapeutics INC. | $132.31 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $108.62 | 2023-2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $108.12 | 2025 | |
| Vivus LLC | $102.72 | 2019-2022 | |
| Companion Medical, INC. | $102.07 | 2019-2020 | |
| Amphastar Pharmaceuticals, INC. | $99.78 | 2024 | |
| Averitas Pharma INC. | $77.77 | 2023-2025 | Qutenza |
| Shire North American Group INC | $72.33 | 2019 | |
| Kyowa Kirin, INC. | $71.85 | 2024-2025 | Crysvita |
| Currax Pharmaceuticals LLC | $69.86 | 2020-2024 | Contrave |
| Ultragenyx Pharmaceutical INC. | $58.72 | 2021-2022 | |
| Zealand Pharma US, INC. | $51.19 | 2020 | |
| Nevro Corp. | $46.95 | 2023-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.28 | 2022 | |
| Amryt Pharma Holdings Ltd | $37.34 | 2023 | Mycapssa |
| Boston Scientific Corporation | $35.07 | 2021-2022 | |
| Shield Therapeutics INC | $34.75 | 2024 | |
| Tolmar, INC. | $33.25 | 2023-2024 | |
| Acella Pharmaceuticals, LLC | $32.69 | 2025 | NP Thyroid 60 |
| Rhythm Pharmaceuticals, INC. | $26.34 | 2025 | Imcivree |
| Alvogen INC | $25.59 | 2025 | Teriparatide |
| Globus Medical, INC. | $24.19 | 2025 | Senza |
| Ipsen Biopharmaceuticals, INC | $23.38 | 2021 | |
| Senseonics, Incorporated | $22.00 | 2019 | |
| Eisai INC. | $21.96 | 2019 | |
| Lifescan, INC. | $21.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.92 | 2019 | |
| Bigfoot Biomedical INC | $18.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.66 | 2020 | |
| Acerus Pharmaceuticals Corporation | $15.36 | 2022 | |
| Glaxosmithkline, LLC. | $15.02 | 2025 | Arexvy, Shingrix |
| Arbor Pharmaceuticals, INC. | $14.15 | 2021 | |
| Halozyme INC | $12.79 | 2023 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$212,802.26 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damaris Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.